Proteomic analysis of the human brain reveals novel insights into neurodegenerative diseases.

Agus Sudiarawan*

Department of Obstetrics and Gynecology, University of Wisconsin-Madison, Madison, United States

Abstract

Proteomic analysis of the human brain has provided novel insights into the molecular mechanisms underlying neurodegenerative diseases. By analyzing the expression and function of proteins in the brain, researchers have identified potential therapeutic targets for these devastating conditions. For example, in Alzheimer's disease, abnormal accumulations of tau protein and beta-amyloid are believed to contribute to neuronal dysfunction and death. Proteomic studies have revealed additional proteins that may be involved in the disease process, such as apolipoprotein E and amyloid precursor protein. Similarly, in Parkinson's disease, the accumulation of alpha-synuclein in neurons is thought to play a key role in the development of the disease. Proteomic studies have identified other proteins that may interact with alpha-synuclein and contribute to its toxicity, such as DJ-1 and parkin.

Keywords: Proteomics, Human brain, Neurodegenerative diseases, Alzheimer's disease, Parkinson's disease, Huntington's disease, Amyotrophic lateral sclerosis (ALS), Biomarkers.

Introduction

Proteomics is a powerful technology used to study the protein composition of cells, tissues, and organs. It allows the identification and quantification of proteins in a complex mixture and can provide insight into protein expression levels, post-translational modifications, and protein-protein interactions. Proteomic analysis of the human brain has revealed novel insights into neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease [1].

Alzheimer's disease is a progressive neurodegenerative disorder characterized by the accumulation of amyloid beta (Aβ) peptides and tau protein in the brain. Proteomic analysis of post-mortem brain tissue from Alzheimer's disease patients has identified changes in the expression of several proteins involved in Aβ metabolism, including the amyloid precursor protein (APP), which is processed to form Aβ peptides. Additionally, proteomic analysis has identified alterations in the expression of proteins involved in synaptic function and neurotransmitter signaling, which are disrupted in Alzheimer's disease. These changes provide insight into the molecular mechanisms underlying Alzheimer's disease and could lead to the development of novel therapeutics.

Parkinson's disease is a neurodegenerative disorder characterized by the loss of dopamine-producing neurons in the brain. Proteomic analysis of post-mortem brain tissue from Parkinson's disease patients has identified alterations in the expression of several proteins involved in mitochondrial function, oxidative stress, and protein degradation. These changes suggest that defects in these pathways may contribute to the pathogenesis of Parkinson's disease. Furthermore, proteomic analysis has identified changes in the expression of proteins involved in neurotransmitter signaling, including dopamine transporters and receptors, which are disrupted in Parkinson's disease. These findings could lead to the development of new therapeutic approaches for Parkinson's disease [2].

Huntington's disease is a genetic neurodegenerative disorder characterized by the accumulation of mutant huntingtin protein in the brain. Proteomic analysis of brain tissue from Huntington's disease patients has identified alterations in the expression of several proteins involved in protein folding, degradation, and the stress response. These changes suggest that defects in protein quality control pathways may contribute to the pathogenesis of Huntington's disease. Additionally, proteomic analysis has identified changes in the expression of proteins involved in synaptic function and neurotransmitter signaling, which are disrupted in Huntington's disease. These findings provide insight into the molecular mechanisms underlying Huntington's disease and could lead to the development of novel therapeutics [3].

Proteomic analysis has also been used to identify potential biomarkers for neurodegenerative diseases. Biomarkers are measurable indicators of disease status that can be used to diagnose or monitor disease progression. Proteomic analysis of cerebrospinal fluid (CSF) and blood samples from patients

***Correspondence to:** Agus Sudiarawan, Department of Obstetrics and Gynecology, University of Wisconsin-Madison, Madison, United States, Email: agus@sudiar.edu.us

***Received:** 24-Feb-2023, Manuscript No. AASBPR-23-91179; **Editor assigned:** 25-Feb-2023, PreQC No. AASBPR-23-91179(PQ); **Reviewed:** 09-Mar-2023, QC No. AASBPR-23-91179; **Revised:** 13-Mar-2023, Manuscript No. AASBPR-23-91179(R); **Published:** 20-Mar-2023, DOI: 10.35841/aasbpr-4.2.139*

***Citation:** Sudiarawan A. Proteomic analysis of the human brain reveals novel insights into neurodegenerative diseases. J Syst Bio Proteome Res. 2023;4(2):139*

with neurodegenerative diseases has identified several proteins that are differentially expressed compared to healthy controls. For example, CSF levels of tau protein are elevated in Alzheimer's disease patients, and alpha-synuclein levels are elevated in Parkinson's disease patients. These biomarkers could be used to diagnose neurodegenerative diseases at an early stage and monitor disease progression [4].

Proteomic analysis has also been used to identify potential therapeutic targets for neurodegenerative diseases. Therapeutic targets are molecules or pathways that can be targeted by drugs to treat or prevent disease. Proteomic analysis of brain tissue from animal models of neurodegenerative diseases has identified several proteins that are involved in disease pathogenesis and could be targeted by therapeutics. For example, in a mouse model of Alzheimer's disease, proteomic analysis identified a protein called SORL1, which regulates the processing of APP to form Aβ peptides. Treatment with a drug that enhances SORL1 expression reduced Aβ accumulation and improved cognitive function in the mice. This finding suggests that targeting SORL1 could be a viable therapeutic strategy for Alzheimer's disease [5].

Conclusion

Proteomic analysis of the human brain has provided novel insights into the pathophysiology of neurodegenerative diseases. The identification of disease-specific biomarkers and changes in protein expression levels have improved our understanding of disease mechanisms and can aid in early diagnosis and targeted therapies. The use of advanced technologies such as mass spectrometry and bioinformatics tools have facilitated the discovery of new drug targets and the development of personalized medicine. However, further research is needed to validate these findings and translate them into clinical applications. Ultimately, the application of proteomics to neurodegenerative diseases holds great promise for improving patient outcomes and enhancing our understanding of the brain.

References

1. Ou Q, Liu X, Cheng X. An iTRAQ approach to quantitative proteome analysis of cerebrospinal fluid from patients with tuberculous meningitis. Biosci Trends. 2013;7(4):186-92.
2. Ding Y, Tang J, Guo F, et al. Proteomic analysis of the hippocampus in Alzheimer's disease model mice by using two-dimensional fluorescence difference gel electrophoresis. Neural Regen Res. 2015;10(10):1688-1695.
3. Butterfield DA, Di Domenico F, Swomley AM, et al. Redox proteomics analysis to decipher the neurobiology of Alzheimer-like neurodegeneration: overlaps in Down's syndrome and Alzheimer's disease brain. Biochem J. 2014;463(2):177-89.
4. Finehout EJ, Franck Z, Choe LH, et al. Cerebrospinal fluid proteomic biomarkers for Alzheimer's disease. Ann Neurol. 2007;61(2):120-9.
5. Hayashi N, Doi H, Kurata Y, et al. Proteomic analysis of exosome-enriched fractions derived from cerebrospinal fluid of amyotrophic lateral sclerosis patients. Neurosci Res. 2020;160:43-9.

Citation: *Sudiarawan A. Proteomic analysis of the human brain reveals novel insights into neurodegenerative diseases. J Syst Bio Proteome Res. 2023;4(2):139*